Visualization of FISH Probes by Dual-Color Chromogenic In Situ Hybridization

被引:16
作者
Hoff, Kirsten [2 ]
Jorgensen, Jan T. [5 ]
Muller, Sven [1 ]
Rongaard, Else [3 ]
Rasmussen, Ole [4 ]
Schonau, Andreas [1 ]
机构
[1] Dako Denmark, Mol Pathol, DK-2600 Glostrup, Denmark
[2] Dako Denmark, Antibody Dev, DK-2600 Glostrup, Denmark
[3] Dako Denmark, Reagent Dev, DK-2600 Glostrup, Denmark
[4] Dako Denmark, Syst Dev, DK-2600 Glostrup, Denmark
[5] CMC Contrast, Res & Dev, Copenhagen, Denmark
关键词
Chromogenic in situ hybridization; CISH; Fluorescence in situ hybridization; FISH; HER2; Signal conversion; TOP2A; BREAST-CANCER; GENE STATUS;
D O I
10.1309/AJCP12MHRTFZJPKW
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The overall purpose of the study was to demonstrate applicability of the DAKO dual-color chromogenic in situ hybridization (CISH) assay (DAKO Denmark, Glostrup) with respect to 4 fluorescence in situ hybridization (FISH) probes: MYC (c-MYC), EGFR, ERBB2 (HER2), and TOP2A. The study showed that the dual-color CISH assay can convert Texas red and fluorescein isothiocyanate (FITC) signals into chromogenic signals with an almost complete 1:1 conversion ratio. Agreement studies between the FISH assays for HER2 and TOP2A and the corresponding CISH conversion assays showed 100% concordance (K values of 1.0) between the CISH and FISH methods for HER2 and TOP2A status. The correlations of the gene copy number to centromere-17 ratios were similarly high, with a correlation coefficient (r) for HER2 and TOP2A of more than 0.95. Owing to the relatively small number of specimens in this study, it is important that the data are confirmed in a larger study.
引用
收藏
页码:205 / 211
页数:7
相关论文
共 12 条
[1]  
[Anonymous], BIOMETRICS
[2]   Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer [J].
Di Palma, S. ;
Collins, N. ;
Faulkes, C. ;
Ping, B. ;
Ferns, G. ;
Haagsma, B. ;
Layer, G. ;
Kissin, M. W. ;
Cook, M. G. .
JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (09) :1067-1068
[3]   Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists [J].
Dietel, M. ;
Ellis, I. O. ;
Hoefler, H. ;
Kreipe, H. ;
Moch, H. ;
Dankof, A. ;
Koelble, K. ;
Kristiansen, G. .
VIRCHOWS ARCHIV, 2007, 451 (01) :19-25
[4]   Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer:: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility [J].
Gong, Y ;
Gilcrease, M ;
Sneige, N .
MODERN PATHOLOGY, 2005, 18 (08) :1015-1021
[5]  
Hauser-Kronberger C, 2004, J MOL HISTOL, V35, P647
[6]   Pharmacodiagnostics and targeted therapies - A rational approach for individualizing medical anticancer therapy in breast cancer [J].
Jorgensen, Jan Trost ;
Nielsen, Kirsten Vang ;
Ejlertsen, Bent .
ONCOLOGIST, 2007, 12 (04) :397-405
[7]   The value of TOP2A gene copy number variation as a biomarker in breast cancer:: Update of DBCG trial 89D [J].
Nielsen, Kirsten Vang ;
Ejlertsen, Bent ;
Moller, Susanne ;
Jorgensen, Jan Trost ;
Knoop, Ann ;
Knudsen, Helle ;
Mouridsen, Henning T. .
ACTA ONCOLOGICA, 2008, 47 (04) :725-734
[8]   Novel horseradish peroxidase substrates for use in immunohistochemistry [J].
Petersen, Kenneth H. .
JOURNAL OF IMMUNOLOGICAL METHODS, 2009, 340 (01) :86-89
[9]   Personalized medicine for breast cancer: moving forward and going back [J].
Ross, Jeffrey S. ;
Symmans, W. Fraser ;
Pusztai, Lajos ;
Hortobagyi, Gabriel N. .
PERSONALIZED MEDICINE, 2006, 3 (04) :363-370
[10]   Chromogenic in situ hybridization -: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples [J].
Tanner, M ;
Gancberg, D ;
Di Leo, A ;
Larsimont, D ;
Rouas, G ;
Piccart, MJ ;
Isola, J .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (05) :1467-1472